# Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00058097** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (estimated)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** tipifarnib
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00058097
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058097, "Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00058097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*